Dexcom looks to expand CGM access as leadership changes take effect

Dexcom has entered 2026 with changes in senior leadership while continuing to push for wider access to CGM technology.

In January, long-time Chief Executive Officer Kevin Sayer stepped down after leading the company for more than a decade. Jake Leach, previously Dexcom’s Chief Operating Officer and President, became CEO on 1 January 2026 and joined the company’s board of directors. Sayer remains involved with the business as Executive Chairman of the board.

Leach has been with Dexcom for more than two decades and has played a key role in the development of its glucose sensing technology, previously serving as Chief Technology Officer before moving into operational leadership roles.

In February, Leach also took on an additional industry leadership role after being appointed chair of the diabetes sector at AdvaMed, the U.S. medtech trade association that represents many of the major diabetes technology companies.

Alongside these leadership changes, Dexcom is closely watching a potential expansion of Medicare coverage for CGM in the United States.

According to reporting by MedTech Dive in February, the U.S. Centers for Medicare and Medicaid Services is expected to consider extending CGM coverage to people with type 2 diabetes who are not using insulin. Dexcom CEO Jake Leach said the company has been waiting for a decision and expects a proposal could emerge in the first half of 2026.

If approved, the policy change could significantly increase access to CGM. Analysts estimate that nearly 12 million people with type 2 diabetes who are not currently taking insulin could potentially benefit from glucose sensors under expanded coverage.

Dexcom has been collecting real-world evidence to support the case for broader access. The company has launched a registry for people with type 2 diabetes who are not using insulin and is running a 300-person randomised controlled trial comparing CGM use with standard care. Results are expected later in 2026.

At the same time, Dexcom has begun rolling out a longer-lasting 15-day version of its G7 sensor in the United States, starting with distribution through durable medical equipment providers before expanding more widely.

__________

Disclaimer

Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre.

Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website whatcgm.comdoes not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.

The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.